Cargando…
A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer
CD47 is a cell surface molecule that inhibits phagocytosis of cells that express it by binding to its receptor, SIRPα, on macrophages and other immune cells. CD47 is expressed at different levels by neoplastic and normal cells. Here, to reveal mechanisms by which different neoplastic cells generate...
Autores principales: | Betancur, Paola A., Abraham, Brian J., Yiu, Ying Y., Willingham, Stephen B., Khameneh, Farnaz, Zarnegar, Mark, Kuo, Angera H., McKenna, Kelly, Kojima, Yoko, Leeper, Nicholas J., Ho, Po, Gip, Phung, Swigut, Tomek, Sherwood, Richard I., Clarke, Michael F., Somlo, George, Young, Richard A., Weissman, Irving L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382276/ https://www.ncbi.nlm.nih.gov/pubmed/28378740 http://dx.doi.org/10.1038/ncomms14802 |
Ejemplares similares
-
Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
por: Chao, Mark P., et al.
Publicado: (2020) -
CD47 blocking antibodies restore phagocytosis and prevent atherosclerosis
por: Kojima, Yoko, et al.
Publicado: (2016) -
Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance
por: Upton, Rosalynd, et al.
Publicado: (2021) -
The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis
por: Jarr, Kai-Uwe, et al.
Publicado: (2022) -
Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
por: Liu, Jie, et al.
Publicado: (2015)